Genomic Disorders Research Centre
Overview
There is a universal demand for significant breakthroughs in the diagnosis, prevention and treatment of the world’s major diseases. New methods and technologies are required to deliver accurate, efficient and cost effective therapies. Human genomics seeks to identify the multiple genes and pathways which underlie common diseases and thereby impact on new drug discoveries and therapy development.
The Genomic Disorders Research Centre was established in 1996 as the first and remains the only organization, world wide, to focus exclusively on gene mutation, its measurement and documentation and its linkage to inherited genetic disease, cancer and common diseases.
This unique centre aims to facilitate improved diagnostics and more rapid progress in the discovery of the cause of disease due to faulty genes. To aid the progress of method development specific diseases are studied to provide practical experience. These diseases are those with the highest incidence of occurrence and include schizophrenia, epilepsy, cancer and mitochondrial disorder.
Identification of the mutation provides the opportunity for proper help for the patient and family and assists in the development of new cures.
Competitive advantages
Familiarity with the international players involved in the human genetic and genomics field, particularly prominent scientists and companies.
Main business focus/
Listing by sector:
- Medical Devices - In vitro diagnostic devices (IVD)
- Diagnostics
- Bioinformatics
Competitive Advantages
Familiarity with the international players involved in the human genetic and genomics field, particularly prominent scientists and companies.
Technology/IP
Three patented methods of Mutation Detection as well as new technologies presently under development.
A patented method simply measuring DNA damage capacity of chemicals.
Corporate Alliances/Partnerships
- Wiley–Liss (the scientific journal Human Mutation)
- Genvartec Pty Ltd
Partnering Opportunities
Joint development of novel simple mutation detection techniques.
Joint development of a novel chemical oxidation method of detecting mutation damaging chemicals which could be an alternative to or be triaged with the Ames and other cell based tests
Partnering Needs
Industry Partners, Development Funding.
Contact Details
| Contact person | Heather Howard |
|---|---|
| Job Title | Executive Officer |
| Address | Level 2, 161 Barry Street |
| City/Suburb | Carlton South |
| State | Victoria |
| h.howard@gdrc.hfi.unimelb.edu.au | |
| Phone | +61 3 8344 1823 |
| Fax | +61 3 9347 6842 |
| Website | http://www.genomic.unimelb.edu.au |
